Vaccines Virtual Conference 2021

• The platforms involved, D-Crypt and POD technologies.
• The idea, prototype and path to development
• The initial experiments and data.
• Road to phase 1 in Humans.
• Breaking the barrier: exploring the possibilities of oral delivery of vaccines

• Establishing your position with regulatory bodies to ensure you are keeping in line with the current practices
• Assessing current data collected to determine the current steps needed of your study
• Liaising with CRO’s to ensure they can fulfil their duty at hand
• Identifying alternative solutions if your current site is not in operation
• Patient safety first: Reviewing your candidates wellbeing to avoid any health risk

Australia is highly regarded as a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials. A US Investigational New Drug (IND) submission is not required to initiate FIH clinical trials in Australia and sponsors are attracted to the region for clinical trials due to high quality data which is recognised by global regulatory agencies. Clinical sites across Australia have adapted well to the COVID-19 pandemic, with all top ten clinical sites still open for either on-site or remote monitoring. World class R&D and clinical research, demonstrated by the innovative COVID-19 vaccine studies conducted over the last 12 months, is the reason why Australia has become a preferred destination for early phase clinical trials

• Acting fast is key – early measures to limit virus spread and incentives for people to adhere to isolation
• Continuing the development of new technologies to enable us to respond even more quickly in future
• Questions remaining and who needs to address them

• Logistics of expediting vaccine trials
• Solutions for alignment of departments and timeline management
• Overall benefits of a unified platform

• How has COVID-19 changed and shaped how we define a healthy vaccines market globally?
• Learning from the policies and models that have driven or enabled innovation in COVID-19 vaccines
• Are these policies and models unique to pandemic response? What positive or negative unintended consequences from COVID-19 vaccines are likely to impact the long-term health of the global vaccines market?
• Learning from COVID-19 vaccines, how can a healthy market support equitable access to future novel vaccines?

• Anticipating what will happen when more vaccines come to market
• Exploring how different vaccines interact in the immune system
• Will we need new COVID vaccines and boosters annually?
• Vaccine deployment and implementation – how do we deliver billions of vaccines globally?

• Exploring overwhelming amount of preclinical data to support the notion that vaccination can control or even eradicate tumours
• Moving forward: the success of a vaccine will depend on our capacity to accurately map the dominant immunosuppressive pathway for each individual patient
• Learning that combining a vaccine with immune checkpoint blockade is an effort in vain when a large part of the tumour has acquired defects in MHC class I presentation
• Understanding the challenge will be to develop technologies that can deliver comprehensive tumour immunomics in a timely and cost-effective fashion

• Misinformation vs disinformation
• Educating HCPs vs the public on misinformation
• Tools to track misinformation in real-time and counter it
• Major sources of vaccine disinformation
• Global examples of social listening strategies
• Amplifying vaccine advocacy voices – how can everyone be part of this?

• What class of combination therapies are most promising? What do the current data tell us? (Conventional Therapy e.g., Chemo/ radiation, Antibody Drug Conjugates, Angiogenesis inhibitors and other targeted therapies etc.)
• Can precision medicine tools help with therapeutic selections?
• Overcoming toxicities of combinations
• Uncovering Intratumoral approaches
• Significant recent and upcoming phase III trials – will they boost the field or set us back?